Candel Therapeutics (CADL) vs 4D Molecular Therapeutics (FDMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Candel Therapeutics (CADL) has outperformed 4D Molecular Therapeutics (FDMT) over the past year, gaining 53.3% versus a gain of 31.5%. Over five years, CADL leads with a -1.7% price change compared with -53.5% for FDMT. Candel Therapeutics is the larger company by market cap ($739.2 million vs $701.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | FDMT |
|---|---|---|
| Share price | $9.66 | $12.70 |
| Market cap | $739.17M | $701.60M |
| 1-day change | -1.63% | +0.87% |
| YTD return | +70.97% | +69.33% |
| 1-year return | +53.33% | +31.47% |
| 5-year return | -1.73% | -53.51% |
| EPS (TTM) | $-1.46 | $-2.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $16.93 |
| 52-week low | $4.35 | $6.96 |
| Distance from 52-week high | -31.00% | -24.99% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +125.16% | +121.18% |
| Average volume | 1.21M | 926.78K |
| Shares outstanding | 76.52M | 55.24M |
| Employees | 55 | 196 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed FDMT by 21.9 percentage points over the past year.
- The two companies sit in different sectors: Candel Therapeutics in Healthcare and 4D Molecular Therapeutics in Health Care.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Healthcare · Biotechnology · 55 employees
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
CADL vs FDMT FAQ
Which is bigger, Candel Therapeutics or 4D Molecular Therapeutics?
Candel Therapeutics (CADL) is larger, with a market capitalization of $739.17M compared with $701.60M for 4D Molecular Therapeutics (FDMT).
Which stock has performed better over the past year, CADL or FDMT?
CADL returned +53.33% over the past 12 months, compared with +31.47% for FDMT (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and 4D Molecular Therapeutics in the same industry?
No. Candel Therapeutics is in the Healthcare sector, while 4D Molecular Therapeutics is in Health Care.